HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients

. 2020 Nov 18;8(1):ofaa566. doi: 10.1093/ofid/ofaa566

B, Relative Hazards of Developing a FIB-4 >1.45 From Fitting a Weighted Cox Regression Model

	Relative Hazards (95% CI) of FIB-4 >1.45
HAART at Baseline	Undjusted		Adjusted^a
	HR (95% CI)	P Value	HR (95% CI)	P Value
TDF/TAF- or LMV-sparing	1.00		1.00
TDF/TAF- or LMV-based	1.38 (0.77–2.47)	.279	0.85 (0.32–2.30)	.756

Abbreviations: HAART, highly active antiretroviral therapy; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; LMV, lamivudine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

^aAdjusted for age, gender, mode of HIV transmission, nation of birth, current CD4 count, and HIV-RNA using inverse probability of weighting.